Alamar NULISA at AAIC Quadruples to 140+ Presentations

Alamar Biosciences (Nasdaq: ALMR) will have its NULISA proteomics platform featured in more than 140 poster and session presentations at the Alzheimer's Association International Conference in London next week, quadrupling the roughly 35 appearances at the 2025 meeting. The company said the count shows the field is adopting its multiplex protein profiling technology for Alzheimer's research.

"We're seeing just how quickly the field has embraced multiplex protein profiling with NULISA," said Steve Williams, MD, PhD, Alamar's chief scientific officer.

The conference runs July 12-15. Alamar will host a workshop on July 14 titled "Beyond p-tau217: Expanding Alzheimer's Insights with Multiplex Protein Profiling." The session will feature new data from the company's eMTBR-Tau and BD-pTau217 assays, which measure tau pathology and neuroinflammation markers in a single workflow.

Thomas K. Karikari, PhD, director of the Biomarker and Neurogenetics Core at the University of Pittsburgh, said the multiplex approach gives "a resolution on tau pathology and disease staging that single-marker assays can't match." He expects the data to help the field move past pTau-217 as the default readout.

The surge in NULISA citations at AAIC follows the launch of Alamar's ARGO HT system, which automates the workflow. Researchers are using the technology to run CNS protein and tau variant panels in a single assay.

Alamar will exhibit at Booth 530 throughout the conference. The company did not disclose any financial terms related to the presentations.